The pharmaceutical business is very aggressive and pushed by innovation. These two information could not be on any clearer show than within the competitors between Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) within the newly created GLP-1 weight-loss house. Whereas Eli Lilly seems just like the winner proper now, Novo Nordisk’s Wegovy tablet is performing higher than anticipated. That is necessary, and it might flip the inventory right into a long-term purchase for dividend lovers.
Novo Nordisk made errors and misplaced the lead
Novo Nordisk was first to market with a GLP-1 weight-loss drug. The one downside is that it could not sustain with the demand for its Wegovy shot. That allowed compounders to enter the U.S. marketplace for the drug, limiting the corporate’s progress alternatives. It additionally gave competitor Eli Lilly an enormous opening when it launched its personal GLP-1 choices, Mounjaro and Zepbound.
Will AI create the world’s first trillionaire? Our crew simply launched a report on the one little-known firm, known as an “Indispensable Monopoly” offering the vital expertise Nvidia and Intel each want. Proceed »
Eli Lilly’s medicine had been additionally more practical, so the corporate’s monetary efficiency was robust whereas Novo Nordisk was principally left taking part in catch-up. Traders reacted by dumping Novo Nordisk and shopping for Eli Lilly. The distinction could not be extra stark, with Novo Nordisk down 40% over the previous three years and Eli Lilly up over 150%.
Nevertheless, there was an necessary change initially of 2026. That was when Novo Nordisk launched a tablet model of Wegovy. Many customers favor capsules over pictures, so this improvement actually opens GLP-1 medicine to extra clients. That is been confirmed, with the pharmaceutical firm seeing even sooner progress with the tablet than with the shot. And the tablet does not look like cannibalizing the shot, so the GLP-1 market is certainly increasing. That is even higher efficiency than the corporate had hoped for, with the tablet producing 1.3 million prescriptions within the first quarter alone. One month later, when the corporate supplied its first-quarter earnings outcomes, the variety of prescriptions had catapulted to 2 million.
Novo Nordisk is dealing with a troublesome 12 months
That mentioned, Novo Nordisk warned traders that 2026 could be a tough 12 months. Wegovy is shedding patent safety in India, which is placing strain on the corporate’s gross sales in that giant market. And Novo Nordisk agreed to chop costs within the U.S. market, which can be weighing on the highest line. Administration expects quantity to offset value over the long run because the Wegovy tablet attracts in additional clients to the GLP-1 house. Given the tablet’s early success, that storyline sounds more and more possible.
